RE
BMY.RT

RBC Europe’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

RBC Europe’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,367
Closed -$1.63K – 1259
2020
Q4 		$1.63K Buy
2,367
+204
+9% +$435 ﹤0.01% 1058
2020
Q3 		$4.87K Hold
2,163
– – ﹤0.01% 908
2020
Q2 		$7.74K Sell
2,163
-400
-16% -$1.44K ﹤0.01% 814
2020
Q1 		$9.74K Hold
2,563
– – ﹤0.01% 714
2019
Q4 		$7.71K Buy
+2,563
New +$6.67K ﹤0.01% 843

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

RBC Europe's BMY.RT Position: Q1 2021 in Review

RBC Europe sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 2,367 shares — an estimated $1.63K sold.

RBC Europe first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $9.74K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • RBC Europe reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • RBC Europe sold 2,367 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1.63K.
  • RBC Europe first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • RBC Europe's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $9.74K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.